Veraxa Biotech AG (VRXA) Stock Analysis
A live, multi-source view of Veraxa Biotech AG (VRXA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Veraxa Biotech AG
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
Sector: Healthcare · Industry: Biotechnology · Germany · veraxa.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Veraxa Biotech AG (VRXA) had a market capitalization of $248.9M; the shares traded in a 52-week range of $1.27 – $27.36 (-83.1% over the year).
- Market cap
- $248.9M
- EPS (trailing)
- $-0.58
- Payout ratio
- 0.0%
- 52-week range
- $1.27 – $27.36
- 52-week change
- -83.1%
- Average volume
- 555,733
- Shares outstanding
- 141.4M
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Veraxa Biotech AG (VRXA) last closed at $1.59 (the last completed close before that scan).
Technicals at the scan: RSI 42 (neutral territory), price -5.4% versus its 20-day average, 20-day versus 50-day average spread -11.6%, MACD histogram 0.08.
Sentiment inputs: 75% of recent Finnhub-scored headlines read bullish; StockTwits 92% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of VRXA; corporate insiders filed 2 buys and 0 sells (2 distinct filers, latest disclosure 2026-08-31). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Oliver Rolf Baumann (1B/0S), Christoph Rudiger Antz (1B/0S). Who is trading what
RapidTradeView pick record
VRXA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Veraxa Biotech AG (VRXA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell VRXA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.